Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Xeris Biopharma Holdings, Inc. XERS
$2.96
+$0.04 (1.20%)
На 18:01, 12 мая 2023
+119.59%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
403001892.00000000
-
week52high
3.00
-
week52low
0.97
-
Revenue
110248000
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-0.72000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 авг 2022 г. в 12:30
Описание компании
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Craig-Hallum | Buy | 28 апр 2022 г. | |
| Mizuho | Buy | Buy | 16 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 16 февр 2022 г. |
| SVB Leerink | Outperform | Outperform | 31 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 31 дек 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| JOHNSON KENNETH ERLAND | A | 269783 | 100000 | 31 янв 2023 г. |
| Hecht Beth | A | 797758 | 350000 | 31 янв 2023 г. |
| PRESTRELSKI STEVEN | A | 719780 | 150000 | 31 янв 2023 г. |
| Pieper Steven | A | 1148912 | 750000 | 31 янв 2023 г. |
| Edick Paul R | A | 2278064 | 750000 | 31 янв 2023 г. |
| Shannon John Patrick Jr | A | 1377806 | 750000 | 31 янв 2023 г. |
| Edick Paul R | A | 1528064 | 20000 | 13 дек 2022 г. |
| Kong Garheng | A | 25000 | 25000 | 08 июн 2022 г. |
| Kong Garheng | A | 65170 | 15000 | 08 июн 2022 г. |
| JOHNSON JOHN | A | 25000 | 25000 | 08 июн 2022 г. |
Новостная лента
Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 14:24
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies Roanna Ruiz - SVB Securities Operator Hello all and warm welcome to the Xeris Biopharma Holding First Quarter 2023 Financial Results Call.
Xeris Biopharma posts record revenue in 1Q
Proactive Investors
09 мая 2023 г. в 09:03
Xeris Biopharma Holdings (NASDAQ:XERS) has started 2023 strongly, achieving record revenue during the first quarter. For the quarter ended March 31, 2023, revenue rose 50.4% to $33.2 million from $22 million in the first quarter of 2022.
Xeris Biopharma secures US patent for XeriSol formulations
Proactive Investors
18 апр 2023 г. в 09:33
Xeris Biopharma Holdings (NASDAQ:XERS) said it has received a US patent covering formulations in its Gvoke product line used to treat severe hypoglycemia. The patent issued by the US Patent and Trademark Office covers methods for using the formulations in treating hypoglycemia as well as manufacturing methods, the biopharma company said.
Xeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJect
Proactive Investors
30 мар 2023 г. в 11:31
Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the agreement, the company said it will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small-volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements.
Xeris Biopharma appoints brand management expert Ricki Fairley to its board of directors
Proactive Investors
29 мар 2023 г. в 16:42
Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced the appointment of Ricki Fairley to its board of directors on March 27, 2023, increasing the size of the company's board to nine members. The growth-oriented biopharmaceutical firm said Fairley has over 35 years of marketing experience including 20 years in brand management at Johnson & Johnson (NYSE:JNJ), Nabisco, Reckitt & Colman, and The Coca-Cola Company (NYSE:KO).